Ignite Creation Date:
2024-05-06 @ 7:41 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06099613
Status:
RECRUITING
Last Update Posted:
2023-10-26
First Post:
2023-10-23
Brief Title:
Study to Safety Tolerability and Immunogenicity of EG-COVII in Healthy Adult
Sponsor:
EyeGene Inc
Organization:
EyeGene Inc
Study Overview
Official Title:
A Phase IIIa Study to Assess the Safety Tolerability and Explore the Immunogenicity of EG-COVII in Healthy Adult Volunteers
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase IIIa Study to Assess the Safety Tolerability and Explore the Immunogenicity of EG-COVII in Healthy Adult Volunteers
Detailed Description:
Subjects will undergo a Screening period beginning up to 2 weeks prior to enrollment the vaccinations will be administered on week 0 and week 3 pre- and post-dose assessment follow-up visits and an end of study EOS or early termination ET visit as applicable
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None